Second-line Immunotherapy for ES-SCLC

At present, the first-line standard treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) is immunotherapy combined with chemotherapy. For patients who relapse within 6 months after first-line chemotherapy, conventionally recommended chemotherapy drugs include topotecan, irinotecan, gemcitabine, paclitaxel or vinorelbine, etc., but due to limited benefits to patients, patients are also recommended to participate in relevant clinical studies. New treatment methods are constantly being explored in second-line treatment, including fluzoparib combined with adebelimumab. The

Trial Details

NCT ID
NCT06853678
Phase
NA
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Adebrelimab
  • Selinexor
  • Nab-paclitaxel
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Age ≥ 18 years old, male or female;
  • ECOG PS score 0-1 points;
  • Expected survival period is not less than 12 weeks;
  • Patients with pathologically (histologically or cytologically) confirmed small cell lung cancer (according to the 2015 classification of the World …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →